Thanks Jacosa, I guess there are no data that would indicate that inflammation plays a greater role in pancreas cancer than in colon cancer (which remains our hope). But it shows that ph 2 studies with their smaller sample size can be misleading - in both ways, actually (it may have been a mistake to stop the colon cancer ph 2 trial).
Jacosa, please remind us : 1) when can the ph3 pancreas cancer study results be expected (or DMB board advice, if still relevant) ? 2) what results (in how many patients) do we have so far that would indicate a better effect on pancreas cancer than on colon cancer ? Thank you
I guess we all agree that OCAT is potentially worth much more than what Axellas is currently offering. The questions that arise here are :
1) Why did Wotton accept an offer of 8.50 per share after rejecting 7.00 and 8.40 (what a difference, lol) ?
2) Why would any other potential party (big pharma or biotech) still wait at this point to come up with a better offer ?